Form 4: Intellia Therapeutics Director Jesse Goodman Reports Significant Equity Grant

Intellia Therapeutics, Inc. Director Jesse Goodman reported the acquisition of 8,000 restricted stock units and 11,450 stock options as part of compensation on June 11, 2025.

Summary

• Jesse Goodman, a Director at Intellia Therapeutics, Inc. (NTLA), reported changes in his beneficial ownership of company securities.
• On June 11, 2025, Mr. Goodman acquired 8,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Mr. Goodman beneficially owns 27,453 shares of Common Stock.
• Additionally, on the same date, Mr. Goodman was granted 11,450 stock options with an exercise price of $8.37 per share.
• These stock options have an expiration date of June 10, 2035, and are set to vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.
• After this transaction, Mr. Goodman beneficially owns 11,450 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports routine insider equity compensation, which is generally a neutral to slightly positive event as it aligns director interests with shareholders, but does not contain significant new financial or operational news.

Positives

• The acquisition of 8,000 Restricted Stock Units (RSUs) aligns the director's interests with shareholders, as RSUs typically vest over time and represent future ownership.
• The grant of 11,450 stock options provides an incentive for the director to contribute to the company's long-term growth and share price appreciation.
• The transactions represent routine equity compensation for a director, indicating standard corporate governance practices.

Negatives

• No negative information is presented in this Form 4 filing, which primarily reports insider equity transactions.

Risks

• This Form 4 filing does not contain information regarding specific company risks. It is a disclosure of insider equity transactions.

Future Outlook

The 11,450 stock options granted to Director Jesse Goodman are set to vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders following the grant date, providing a future incentive for performance.

Management Comments

• The filing indicates that the transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), suggesting a pre-arranged equity compensation plan.

Industry Context

This Form 4 filing reflects a standard practice of equity compensation for directors in the biotechnology or pharmaceutical industry, aiming to align executive interests with long-term shareholder value. Such grants are common for companies like Intellia Therapeutics, which often rely on long-term incentives to retain key talent.

Comparison to Industry Standards

• This type of equity grant (RSUs and stock options) is a common form of director compensation across the biotechnology and broader public company landscape.
• While specific grant sizes vary by company size, stage, and individual contribution, the structure aligns with typical industry practices for incentivizing and retaining board members.
• No specific comparable companies or projects are mentioned in the document to provide a direct comparison of results.

Corporate Governance

Related Party Transactions

• The acquisition of Restricted Stock Units and stock options by Director Jesse Goodman from Intellia Therapeutics, Inc. constitutes a related party transaction, specifically equity compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially fostering greater commitment to shareholder value creation.

Next Steps

• Vesting of the 8,000 Restricted Stock Units (RSUs) and 11,450 stock options according to their specified schedules.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership